INTRODUCTION
There is robust evidence that genes influence susceptibility to both bipolar (BD) 1, 2 and unipolar disorder (UP). 3 Genome-wide association studies (GWAS) in large samples have the power to identify susceptibility loci at the high levels of statistical support that are required when testing the whole genome. 4 For example, GWAS have identified a number of loci that show strong support for their association with BD. Genome-wide support has been shown for common variation within CACNA1C, ANK3, NCAN and more recently ODZ4.
5--7
The recent molecular genetic findings have further provided evidence that particular genes, and hence biological processes and systems, contribute susceptibility across psychiatric illnesses not just relating to one diagnostic entity. 7--9 For example, genetic studies have shown that polymorphisms in the genes PCLO, CACNA1C and loci on chromosome 3p21.1 may confer susceptibility to both recurrent unipolar depression and BD. 3,10--13 Similarly, genes and chromosomal regions have been shown to contribute susceptibility to both schizophrenia (SZ) and BD, CACNA1C, 11 ZNF804a, 14 PBRM1, NRGN and the extended MHC region. 15 The Psychiatric Genome-Wide Association Study Consortium Bipolar Disorder 7 group (PGC-BD) has performed a combined analysis of GWAS data from 7481 BD individuals and 9250 control individuals, and identified four regions that contain singlenucleotide polymorphisms (SNPs) with nominal P-value o5 Â 10 À8 in the discovery sample. Association was detected at ANK3, SYNE1, an intergenic SNP on chromosome 12q13, and at ODZ4. Genome-wide significant association was confirmed for CACNA1C and for the novel gene ODZ4, although additional support for association was not observed at ANK3 and SYNE1 in the independent replication sample.
Given the interest in SYNE1, but lack of genome-wide significant support for this locus, we sought to test association at the index SNP from the PGC study (the intronic SYNE1 SNP, rs9371601) in an independent BD replication sample. Further we examined the polymorphism in a recurrent major depression case--control sample.
MATERIALS AND METHODS Samples
All of the participants in these studies were unrelated, white, living in the British Isles and were of European descent. The protocols and procedures were approved by the relevant ethics review panels where patients were recruited. Cases were excluded if they (i) had only experienced mood or psychotic illness as a result of alcohol or substance dependence; (ii) had a history of intravenous drug use (for unipolar recurrent major depression cases); (iii) had experienced mood or psychotic illness secondary to medical illness or medication; or (iv) were biologically related to another study participant. A similar methodology was used for assessment of bipolar and unipolar cases: a semistructured lifetime ever psychiatric interview (Schedules for Clinical Assessment in Neuropsychiatry), 16 a review of the available case notes and completion of the Operational Criteria (OPCRIT) checklist of items of psychopathology, 17 which has been shown to be valid for use in studies of mood disorders, 18 followed by clinical ratings and a best-estimate lifetime diagnosis according to the Research Diagnostic Criteria. 19 In cases where there was doubt as to the best-estimate lifetime diagnosis, diagnostic and clinical ratings were made by at least two members of the research team blind to each other's ratings, and a consensus diagnosis was made.
BD cases
The 1527 BD cases (24% male) had a mean age at first impairment of 22 (s.d. 9) years. These BD cases have not been used in a previous GWAS or other studies at this locus. The individuals were recruited if they suffered with a major mood disorder, in which clinically significant episodes of elevated mood had occurred. This was defined as a lifetime diagnosis of a bipolar mood disorder according to Research Diagnostic Criteria, 19 and included bipolar I disorder (63% cases), bipolar II disorder (29% cases), schizoaffective disorder and bipolar type (8% cases).
Unipolar recurrent major depression cases
In addition to the exclusion criteria described above, unipolar cases were also excluded if they (i) had a first-or second-degree relative with a diagnosis of bipolar affective disorder or SZ, schizotypal disorder, persistent delusional disorder, acute and transient psychotic disorders, or schizoaffective disorder (all of which increase the likelihood of developing BD or a psychotic disorder); or (ii) had ever experienced mood-incongruent psychosis or psychosis outside of mood episodes.
All cases met the DSM-IV 20 criteria for recurrent unipolar major depressive disorder (1159 cases, 34% male, mean age 48 (s.d. 13) years, mean age at onset 22 (s.d. 14 years)); further information on key variables was available for 331 individuals, 14% of whom had a lifetime occurrence of one or more mood congruent psychotic features. These samples are included in the PGC-MDD data set.
Controls
The controls, which were not screened to exclude presence of psychiatric illness, came from two sources: the 1958 Birth Cohort Controls and the UK blood service controls. The characteristic and recruitment of both are described in Wellcome Trust Case Control Consortium (WTCCC), 2007. 21 A total of 2592 control samples were genotyped in this study and make up the 'Full control sample'. Of this full sample of controls, 1579 have not been used in previous studies at this locus, and we call these the 'independent' controls. The remaining 1013 controls had been included in the earlier WTCCC GWAS 21 and PGC-BD 7 meta-analysis, and we call these 'WTCCC' controls. Within the entire control sample, 50% were male, and 52% within the independent sample set.
In summary, the control samples consisted of the following:
(i) The 'independent control sample' set made up of 1579 UK blood donors. These control samples have not been used in any studies previously reported independently or in meta-analyses. (ii) The 'WTCCC control sample' set made up of 1013 samples, of which 176 came from the 1958 Birth Cohort (also known as the National Child Development Study) and 837 from the UK blood donors, all of which were used in the WTCCC GWAS. 21 
Genotyping
Individual genotyping was performed using the Sequenom MassARRAY iPlex platform (Sequenom, San Diego, CA, USA). All assays were optimized in the 30 reference CEU (European ancestry in Utah) parent--offspring trios, as detailed in the International Hapmap Project (http://www.hapmap.org). All plates for genotyping contained a mixture of cases, controls, blanks and CEU samples to provide a measure of genotyping accuracy. All genotypes were called blind to sample identity and affection status.
Statistical analysis
Single-locus association test (Cochran--Armitage Trend test) and assessment of marker Hardy--Weinberg equilibrium in the association samples were performed using PLINK 1.07 (http://pngu.mgh.harvard.edu/~purcell/ plink/).
22
Consistent with our previous phenotypic analyses of the WTCCC BD data set 23 and CACNA1C data, 11 we undertook an exploratory analysis using logistic regression to seek one or more phenotype variables that showed an enhanced signal at the risk allele. In the bipolar sample, we tested the following clinical variables: gender, age at onset of illness, lifetime occurrence of psychosis, Bipolar affective Disorder Dimension Scale (BADDS) 24 mania score, BADDS depression score, BADDS psychosis score, BADDS incongruence score, lifetime occurrence of suicidal ideation and lifetime occurrence of rapid cycling. In the unipolar samples, we tested the following clinical variables: age at onset, lifetime occurrence of psychosis and BADDS depression score.
Meta-analysis
Results were combined by fixed-effects meta-analyses using PLINK 1.07 (ref. 22) to estimate a common odds ratio (OR) weighted by individual study's standard error. We combined our data and the PGC combined GWAS and replication samples, which had been previously adjusted by a lambda of 1.176. 7 
RESULTS
Genotyping call rate for the SNP rs9371601 was excellent, call rate ¼ 99.9%, and was in Hardy--Weinberg equilibrium (P-value, P40.05) for both BD and UP cases and all control samples. The genotyping concordance rate observed between the controls present both in the WTCCC study and successfully genotyped in this study by sequenom was (n ¼ 1008) 99.8%.
Comparison of BD cases with independent controls showed significant overrepresentation of the previous BD risk allele, T (minor allele), in cases compared with controls (Trend P-value ¼ 0.0095, OR ¼ 1.148; Table 1 ).
We performed a fixed-effects meta-analysis combining our BD data and the PGC-BD combined data (both primary and replication data). 7 We observed genome-wide significant evidence for association with rs9371601 in SYNE1 (P ¼ 2.9 Â 10
À8
, OR ¼ 1.104; Table 2 ). A similar comparison of the UP cases with independent controls showed a trend toward significant overrepresentation of the T allele in cases (Trend P ¼ 0.065); however, we observed a similar effect size as seen with BD (OR ¼ 1.111; Table 1 ). Analysis of the unipolar depression cases with all available genotyped control data (full control sample, n ¼ 2592) again showed similar effect size (OR ¼ 1.118) and reached significant levels of association at the P ¼ 0.05 level (P ¼ 0.032).
Comparison of the genotype and allele distributions in the two case samples (BD and UP) did not show significant differences (w 2 -analysis of 3 Â 2 and 2 Â 2 contingency tables, P40.05).
In the exploratory phenotypic analysis of the BD and UP sample, none of the variables examined showed an enhanced signal at the risk allele. We observed no effect of gender on the association.
DISCUSSION
Within the PGC-BD data set, the SNP rs9371601 within SYNE1 showed association with BD with a nominal P-value o5 Â 10 À8 ; however, this association was not replicated in the large independent sample set. 7 This SNP lies in intron 16 of SYNE1 and currently is not thought to be functional. We have replicated this association in our independent BD case--control sample with the same risk allele, T, at rs9371601. Combining our data with the total PGC-BD data (both primary and replication sample) showed genome-wide significant evidence for association for this SNP in SYNE1 (P ¼ 2.9 Â 10 À8 ). We have also shown that the same risk allele is associated with risk of recurrent unipolar depression. The effect sizes were similar for both bipolar and recurrent unipolar depression cases, and we found no statistically significant differences between the genotype or allele distributions across the two case sets, although each differed significantly from the control individuals.
Our association with similar effect size in recurrent unipolar depression at SYNE1 is consistent with findings in a previous metaanalysis of BD and major depressive disorder GWAS. 12 Of the 14 SNPs reported that lie within SYNE1, 1 SNP (rs214961) is in complete linkage disequilibrium (D 0 ¼ 1, r 2 ¼ 1) with rs9371601, the SNP reported in this study, and showed increased support in the combined analysis with a meta-analysis P-value of 9 Â 10 À6 . SYNE1 encodes for Nesprin-1. The Nesprins, 1--4, are part of the complex that links the nucleoskeleton to the cytoskeleton (LINC). 25 Variation at SYNE1 is known to cause spinocerebellar ataxia autosomal recessive type 8 (also known as autosomal recessive cerebellar ataxia type 1), 26 Emery-dreifuss muscular dystrophy type 4 (ref. 27 ) and an autosomal recessive form of congenital muscular dystrophy, myogenic arthrogryposis. 28 Exploration of the phenotype variables of the BD and recurrent unipolar depression sample did not suggest that this locus influences any particular aspects of the illnesses. We also note that gender did not influence the observed association (and, hence, any differences in gender distribution in our case and control samples did not cause or influence the findings). The SNP forming the focus of the current report has not been shown to be associated with risk for SZ, in either the GWAS study by O'Donovan et al.
14 (P-value ¼ 0.355, OR (95% confidence interval) ¼ 1.07 (0.93--1.24)) or in the International Schizophrenia Consortium data set 29 (P-value ¼ 0.79, OR (95% confidence interval) ¼ 1.01 (0.93--1.09)). Data from the Psychiatric Genomewide Association Study Consortium SZ group combining all recent SZ GWAS data 30 including the two studies mentioned above gave a P-value of 0.063 (OR ¼ 1.04).
Our findings constitute direct molecular evidence consistent with a genetic overlap between BD and UP. However, it is important to consider possible methodological issues that may affect our findings. First, while recognizing the possibility of misdiagnosis contributing to our finding and being fully aware of the limitations of current diagnostic approaches, 8 we note that great care was taken to apply rigorous clinical methodology to the assessment and classification of the BD and UP cases in order to minimize misdiagnosis: all unipolar cases were excluded if they had a firstor second-degree relative with a diagnosis of the following; bipolar affective disorder or SZ, schizotypal disorder, persistent delusional disorder, acute and transient psychotic disorders or schizoaffective disorder, all of which increase the likelihood of the individual developing BD or a psychotic disorder. Second, a further methodological issue to be considered is that the control individuals used in our study were not screened to exclude psychiatric illness. This will lower the power to detect differences from cases and although it would not have a large impact for BD, with a lifetime prevalence of around 1%, it may well have an effect when studying unipolar depression that is more common. 31 However, despite this potential reduction in power, we still observed a significant association with unipolar depression with a similar effect size to BD. Third, it is important to acknowledge that caution is required to avoid overinterpreting any single finding of overlapping genetic susceptibility between BD and UP, particularly given the modest statistical significance of the finding in our sample for UP. None-the-less, the observed similarity of estimated effect size between BD and UP at this locus, within the context of prior evidence of genetic overlap from both classical genetic epidemiological 32, 33 and recent molecular genetic studies, 10--13 suggests that our findings of overlap cannot easily be dismissed as an artifact.
In summary, within our UK sample we found the same risk allele at SYNE1 increases risk to BD, at a genome-wide significance level, and had a similar association in our recurrent major depression sample. Our data provide support for further work at this locus. 
